• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • PNS Leadership Learning Series
    • Fellows Learning Series
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
  • For Patients
    • Patient Stories
    • Patient Resources
    • Find a Physician
    • MicroLead™ Safety
  • About Us
  • News & Events
    • News
    • Events
    • Press Room
  • Careers
  • Contact Us

SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFA

March 1, 2021

Results Highlight Clinically Significant and Durable Reductions in Chronic Low Back Pain Following Treatment

Cleveland, Ohio- March 1, 2021- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of percutaneous peripheral nerve stimulation (PNS) for patients with recurrent low back pain who underwent a radiofrequency ablation (RFA) procedure at least 6 months prior.

The study, published in Pain Medicine, evaluated patients who experienced a return of chronic lower back pain following RFA treatment, which denervates the multifidus and often requires re-treatment every six to eighteen months. In contrast, PNS of the medial branch nerve results in activation of the multifidus muscles, a key postural muscle in the spine.

With use of the SPRINT PNS System, a majority of participants in the study saw clinically significant reductions in pain intensity following a 60-day treatment period, with commensurate improvements in functional outcomes.

  • 62% average pain relief (p < 0.001)
  • 21 point reduction on the Oswestry Disability Index (p =0.0002)
  • 61% improvement in pain interference (p <0.0001)

At five months following treatment 93 percent of patients reported sustained and clinically meaningful improvements.

“In many patients RFA is a great therapy for chronic low back pain, but when it doesn’t provide pain relief or a durable outcome the data demonstrates that stimulation, rather than ablation of the medial branch nerves, can be effective.  The healthy afferent signals induced following multifidus activation in response to focal and robust medial branch stimulation may be much more important than we’ve previously realized.  In fact, we may well be entering the ‘Decade of the Multifidus’ as it relates to the prevention and treatment of low back pain,” said lead author Dr. Timothy Deer, President and CEO of The Spine & Nerve Centers of the Virginias.

About the SPRINT® PNS System

The SPRINT® PNS System, by SPR® Therapeutics, marks an innovative shift in the treatment of pain. Our breakthrough, restorative, 60-day treatment is a First-Line™ PNS option uniquely designed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve damage or the risk of addiction. The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and is cleared for use up to 60 days. Recognized by leading pain management centers, the breakthrough neuromodulation treatment offers a patient-preferred alternative to more invasive options.

For additional information regarding safety and efficacy visit www.SprintPNS.com

About SPR Therapeutics, Inc.
SPR Therapeutics is a privately-held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a safe, drug-free, surgery-free solution to manage their chronic pain.

More information can be found at www.SPRTherapeutics.com.

# # #

MKT-000258(01)

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: NewsTag: Back Pain, multifidus, peripheral nerve stimulation, PNS, RFA, SPRINT PNS
Previous Post: « SPRINT PNS System Regional Training Labs 2021
Next Post: Researchers Unveil a New Theory Explaining Long-term Pain Relief »

Sidebar

Archives

Recent News

The Impact of COVID-19 on Chronic Pain and Stress: A Discussion with Dr. Mehul Desai

Are stress and pain related? Which is the chicken and which the egg? Can the one lead to the other? According to a 2017 study published on the National Center …

Could 60-Day Percutaneous PNS Treatment Lead to Sustained Pain Relief by Reconditioning the CNS?

Authors: Chief Scientific Officer Josh Boggs, PhD; Senior Research Manager, Nate Crosby

Researchers Unveil a New Theory Explaining Long-term Pain Relief

SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFA

Is the SPRINT PNS (Peripheral Nerve Stimulation) System an option for me?

Tags

Back Pain choosing a patient for PNS Chronic Pain CNS Common Pain Syndromes conventional PNS CRPS Fellows webinar First-Line PNS Knee Pain Lab medial branch multifidus Neuropathic Pain pain appointment pain care pain care continuum pain doctor pain physician pain relief pain treatment PAINWeek Pain Week LIVE Virtual Conference Patients Patient Story peripheral nerve stimulation PNS PNS training PSPS PSPS Virtual Annual Conference questions to ask about pain questions to ask a pain doctor recondition CNS Redefining Chronic Pain regional training research RFA see a pain doctor Shoulder Pain SPRINT SPRINT PNS SPRITN PNS Training Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 110
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Quick Links

  • Product
  • For Physicians
  • For Patients
  • About Us
  • News & Events
  • Careers
  • Contact Us

Info Links

  • Important Safety Information
  • Compliance
  • FCOI Policy
  • COVID-19 Response

Recent News Headlines

The Impact of COVID-19 on Chronic Pain and Stress: A Discussion with Dr. Mehul Desai

Could 60-Day Percutaneous PNS Treatment Lead to Sustained Pain Relief by Reconditioning the CNS?

WAPMU-SPRINT PNS System Training Lab

SPRINT PNS System Regional Training Lab – Salt Lake City

SPR Therapeutics

The SPRINT PNS System is indicated for up to 60 days in the back and/or extremities for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the craniofacial region. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.

Copyright © 2021 SPR Therapeutics. All Rights Reserved. | Privacy & Terms of Use | Patent Information | Product Terms & Conditions